Peritoneal Cancer Pipeline Summary

DelveInsight’s, “Peritoneal Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peritoneal Cancer: Understanding

Peritoneal Cancer: Overview

Peritoneal cancer refers to malignant tumors involving the peritoneum, the thin membrane lining the abdominal cavity and covering many abdominal organs. It may arise primarily from the peritoneum, such as primary peritoneal carcinoma or malignant peritoneal mesothelioma, or more commonly represent peritoneal metastases (peritoneal carcinomatosis) from ovarian, colorectal, gastric, appendiceal and other gastrointestinal cancers. Peritoneal involvement is considered an advanced pattern of cancer spread and can be associated with substantial morbidity.

Clinical manifestations vary with tumor burden and the underlying primary cancer, but commonly include abdominal distension, pain or discomfort, increasing abdominal girth, nausea, vomiting, reduced appetite and unintended weight loss. Ascites is particularly common and may cause early satiety, breathlessness and progressive abdominal swelling. Advanced disease can produce bowel or ureteral obstruction, altered bowel habits, fatigue and nutritional deterioration, while some patients remain relatively asymptomatic until the peritoneal disease becomes extensive.

Peritoneal malignancy most frequently develops through transcoelomic dissemination, in which tumor cells detach from a primary abdominal or pelvic tumor, enter the peritoneal cavity and implant on peritoneal surfaces. Tumor cells can subsequently proliferate, invade the peritoneal tissue and spread along pathways of peritoneal fluid circulation, producing multiple nodules and infiltrative deposits. Ovarian and gastrointestinal cancers have a particularly strong tendency toward peritoneal spread, while tumor biology, stage, histology and the extent of primary disease influence the risk and pattern of dissemination.

Diagnosis generally combines clinical assessment, laboratory investigations and imaging, particularly contrast-enhanced CT to identify ascites, peritoneal nodules, omental infiltration and other metastatic sites; diagnostic laparoscopy and biopsy may be required for definitive characterization and assessment of disease extent. Treatment depends on the primary tumor, distribution and volume of peritoneal disease, and patient fitness, and may include systemic chemotherapy, targeted or immunotherapies where appropriate, and palliative procedures. In carefully selected patients with limited peritoneal disease, cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) may provide prolonged disease control; however, patient selection and the feasibility of complete cytoreduction are critical.

“Peritoneal Cancer - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Peritoneal Cancer pipeline landscape is provided which includes the disease overview and Peritoneal Cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

Peritoneal Cancer Emerging Drugs Chapters

This segment of the Peritoneal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal Cancer Emerging Drugs

Raludotatug deruxtecan: Daiichi Sankyo and Merck & Co.

Raludotatug deruxtecan (R-DXd) is an investigational CDH6-directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo and jointly developed globally with Merck & Co. for CDH6-expressing solid tumors, including ovarian, primary peritoneal and fallopian tube cancers. It consists of a humanized anti-CDH6 antibody linked to a topoisomerase I inhibitor DXd payload, designed to selectively deliver cytotoxic therapy to CDH6-expressing tumor cells. For peritoneal cancer, R-DXd is being evaluated in the Phase III trial in patients with platinum-resistant, high-grade ovarian, primary peritoneal or fallopian tube cancer. The program has received FDA Breakthrough Therapy Designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers previously treated with bevacizumab.

Utidelone: Beijing Biostar Pharmaceuticals

Utidelone (UTD2) is an investigational oral epothilone analog and next-generation microtubule stabilizer developed by Beijing Biostar Pharmaceuticals for advanced cancers, including primary peritoneal cancer. It binds to tubulin, promotes microtubule polymerization and prevents depolymerization, thereby disrupting mitosis and inducing apoptosis in tumor cells. For platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, Utidelone capsules are being evaluated in Phase II study. The study is assessing different once-daily and twice-daily dosing regimens, with safety, dose-limiting toxicity, objective response rate, disease control rate and progression-free survival among the key outcomes.

TORL-1-23: TORL BioTherapeutics

TORL-1-23 (ixotatug vedotin) is an investigational Claudin-6 (CLDN6)-targeted antibody–drug conjugate (ADC) developed by TORL BioTherapeutics for CLDN6-positive solid tumors, including ovarian, fallopian tube and primary peritoneal cancers. The ADC is designed to selectively bind CLDN6-expressing tumor cells and deliver its cytotoxic payload, thereby inducing tumor-cell death while limiting exposure to normal tissues with little or no CLDN6 expression. For peritoneal cancer, it is being evaluated in the CATALINA-2 Phase II study in women with CLDN6-positive platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who have received 1–3 prior lines of therapy. TORL-1-23 is currently in Phase II development, with objective response rate as the primary efficacy endpoint; the program has also received FDA Fast Track Designation.

Sovilnesib: Volastra Therapeutics

Sovilnesib (formerly AMG 650) is an investigational oral KIF18A inhibitor developed by Volastra Therapeutics for cancers characterized by high chromosomal instability, including ovarian, fallopian tube and primary peritoneal cancer. By inhibiting KIF18A, a mitotic kinesin, sovilnesib is designed to disrupt chromosome segregation and preferentially induce cell death in tumors with high chromosomal instability. For peritoneal cancer, it is being evaluated in Phase Ib study in patients with platinum-resistant or refractory high-grade serous ovarian, fallopian tube or primary peritoneal cancer. The randomized dose-optimization study evaluates once-daily oral sovilnesib across multiple dose levels, with the aim of establishing the recommended Phase II dose (RP2D) while assessing safety, pharmacokinetics and preliminary efficacy.

Further product details are provided in the report……..

Peritoneal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Peritoneal Cancer

There are approx. 65+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo and Merck & Co.

Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal Cancer drugs.

Peritoneal Cancer Report Insights

• Peritoneal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritoneal Cancer drugs?
• How many Peritoneal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daiichi Sankyo
• Merck & Co.
• Beijing Biostar Pharmaceuticals
• AstraZeneca
• Volastra Therapeutics
• TORL BioTherapeutics
• Alphamab Oncology
• Sichuan Baili Pharmaceutical Co., Ltd.
• CSPC Pharmaceutical Group Limited
• Chong Kun Dang Pharmaceutical
• Innovent Biologics
• Regeneron Pharmaceuticals
• Epitopea Ltd
• Generate Biomedicines
• Artios Pharma Ltd
• Avenzo Therapeutics, Inc.
• NextCure, Inc.
• Recursion Pharmaceuticals, Inc.
• OncoC4, Inc.
• Toray Industries, Inc
• RemeGen

Key Products

• Raludotatug deruxtecan
• Utidelone
• AZD5335
• Sovilnesib
• TORL-1-23
• JSKN003
• BL-M07D1
• SYS6043
• CKD-215
• IBI354
• TORL-1-23
• REGN5668
• CryptiVax-1001
• GB-5267
• ART0380
• AVZO-021
• SIM0505
• GTAEXS617
• ONC-392
• TRK-950
• RC88